Nothing Special   »   [go: up one dir, main page]

EA201591286A1 - Количественная оценка эффективности кэп матричной рнк - Google Patents

Количественная оценка эффективности кэп матричной рнк

Info

Publication number
EA201591286A1
EA201591286A1 EA201591286A EA201591286A EA201591286A1 EA 201591286 A1 EA201591286 A1 EA 201591286A1 EA 201591286 A EA201591286 A EA 201591286A EA 201591286 A EA201591286 A EA 201591286A EA 201591286 A1 EA201591286 A1 EA 201591286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mrna
efficiency
cep
capped
quantitative estimation
Prior art date
Application number
EA201591286A
Other languages
English (en)
Inventor
Майкл Хартлейн
Франк Дероза
Ануша Диаз
Original Assignee
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетик Терапис, Инк.
Publication of EA201591286A1 publication Critical patent/EA201591286A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Настоящее изобретение предоставляет, помимо прочего, способы количественной оценки эффективности кэпирования мРНК, в особенности мРНК, синтезированной in vitro. В некоторых вариантах осуществления способы согласно настоящему изобретению включают предоставление образца мРНК, содержащего кэпированную и некэпированную мРНК, предоставление кэп-специфического связывающего вещества в условиях, которые позволяют образовать комплекс между кэп-специфическим связывающим веществом и кэпированной мРНК, и количественное определение количества комплекса в сравнении с контролем с подсчетом эффективности кэпирования мРНК.
EA201591286A 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк EA201591286A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784253P 2013-03-14 2013-03-14
PCT/US2014/027602 WO2014152673A1 (en) 2013-03-14 2014-03-14 Quantitative assessment for cap efficiency of messenger rna

Publications (1)

Publication Number Publication Date
EA201591286A1 true EA201591286A1 (ru) 2016-02-29

Family

ID=50625146

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591286A EA201591286A1 (ru) 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк

Country Status (14)

Country Link
US (4) US10626439B2 (ru)
EP (2) EP3495505B1 (ru)
JP (1) JP2016515216A (ru)
CN (1) CN105209633A (ru)
AU (1) AU2014239264A1 (ru)
BR (1) BR112015022141A2 (ru)
CA (1) CA2903488A1 (ru)
DK (1) DK2971098T3 (ru)
EA (1) EA201591286A1 (ru)
ES (1) ES2708562T3 (ru)
MX (1) MX2015011945A (ru)
PL (1) PL3495505T3 (ru)
TR (1) TR201901396T4 (ru)
WO (1) WO2014152673A1 (ru)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
SMT201900445T1 (it) 2011-06-08 2019-09-09 Translate Bio Inc Composizione di nanoparticelle lipidiche e metodi per il rilascio di mrna
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
US10626439B2 (en) 2013-03-14 2020-04-21 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger RNA
DK2970955T3 (en) 2013-03-14 2019-02-11 Translate Bio Inc METHODS FOR CLEANING MESSENGER RNA
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
US9970047B2 (en) 2013-03-14 2018-05-15 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger RNA
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
MX2016005237A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
SE539096C2 (en) * 2015-03-18 2017-04-04 C Conjunction Ab A method, system and software application for providing context based commercial information
EP4101930A1 (en) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
DK4140491T5 (da) 2015-09-21 2024-07-22 Trilink Biotechnologies Llc Fremgangsmåde til syntetisering af RNA'er med 5'-kappe
US10144942B2 (en) 2015-10-14 2018-12-04 Translate Bio, Inc. Modification of RNA-related enzymes for enhanced production
US20190225644A1 (en) * 2015-10-16 2019-07-25 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
US11866754B2 (en) * 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
US20210108252A1 (en) * 2015-12-09 2021-04-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
HRP20230050T1 (hr) 2016-05-18 2023-03-03 Modernatx, Inc. Polinukleotidi koji kodiraju interleukin-12 (il12) i njihova upotreba
GB201615233D0 (en) * 2016-09-08 2016-10-26 Bbi Solutions Oem Ltd Solid Phase Conjugate
MA47606A (fr) 2017-02-27 2021-04-07 Translate Bio Inc Procédés de purification d'arn messager
MA47605A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Procédés de purification d'arn messager
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
CA3066767A1 (en) 2017-06-30 2019-01-03 Codexis, Inc. T7 rna polymerase variants
CN111032863B (zh) * 2017-06-30 2024-10-22 科德克希思公司 T7 rna聚合酶变体
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
AU2019355177A1 (en) 2018-10-04 2021-05-06 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
SG11202102703VA (en) 2018-10-26 2021-04-29 Illumina Inc Modulating polymer beads for dna processing
CN113166790A (zh) 2018-11-08 2021-07-23 川斯勒佰尔公司 信使rna纯化的方法和组合物
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
EP3897702A2 (en) 2018-12-21 2021-10-27 CureVac AG Rna for malaria vaccines
BR112021022910A2 (pt) 2019-05-15 2022-01-25 Translate Bio Inc Métodos para purificação de rna mensageiro
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
CN112626177A (zh) * 2019-10-09 2021-04-09 华中科技大学 一种快速定量检测rna加帽效率的方法
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
KR20230047086A (ko) * 2020-06-26 2023-04-06 카리스마 테라퓨틱스 인코포레이티드 면역 세포의 mRNA 형질감염
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN113337558A (zh) * 2020-08-20 2021-09-03 深圳市瑞吉生物科技有限公司 一种Cap2结构5`帽子类似物及其制备方法和应用
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
EP4312999A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20240229075A1 (en) 2021-05-03 2024-07-11 CureVac SE Improved nucleic acid sequence for cell type specific expression
EP4351777A1 (en) * 2021-06-07 2024-04-17 The University of Massachusetts Apparatus and method for continuous production of rna
IL309502A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
AU2022430003B9 (en) * 2022-02-28 2023-11-23 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for rna capping and uses thereof
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
EP4323543B1 (en) * 2022-04-15 2024-10-30 Thermo Finnigan LLC Method for quantitative monitoring of mrna capping efficiency
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
WO2024161314A1 (en) * 2023-01-31 2024-08-08 Seqirus Inc. Capping assay
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN116640833B (zh) * 2023-06-01 2024-11-26 中国医学科学院医学生物学研究所 一种利用毛细管电泳技术自动化批量检测mRNA加帽率的方法
CN116426610B (zh) * 2023-06-08 2024-01-05 启辰生生物科技(珠海)有限公司 一种LC-MS法准确定量mRNA加帽效率的方法
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
DE4140463A1 (de) 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6043060A (en) 1996-11-18 2000-03-28 Imanishi; Takeshi Nucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
WO2001016149A2 (en) 1999-08-30 2001-03-08 Roche Diagnostics Gmbh 2-azapurine compounds and their use
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
CA2437558A1 (en) 2001-01-31 2002-08-08 The Board Of Regents Of The University Of Texas System Method and apparatus for the confinement of materials in a micromachined chemical sensor array
DE60327775D1 (de) * 2002-06-24 2009-07-09 Exiqon As Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
WO2007120863A2 (en) 2006-04-14 2007-10-25 Epicentre Technologies Kits and methods for generating 5' capped rna
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US20100035249A1 (en) * 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10626439B2 (en) * 2013-03-14 2020-04-21 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger RNA
US9970047B2 (en) 2013-03-14 2018-05-15 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger RNA
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
ES2960936T3 (es) 2018-04-25 2024-03-07 Ethris Gmbh Formulaciones a base de lípidos para el suministro de ARN

Also Published As

Publication number Publication date
ES2708562T3 (es) 2019-04-10
AU2014239264A1 (en) 2015-08-27
US10626439B2 (en) 2020-04-21
WO2014152673A1 (en) 2014-09-25
PL3495505T3 (pl) 2025-01-13
TR201901396T4 (tr) 2019-02-21
CN105209633A (zh) 2015-12-30
DK2971098T3 (en) 2019-02-18
US20160002705A1 (en) 2016-01-07
US20200318156A1 (en) 2020-10-08
MX2015011945A (es) 2015-12-01
EP3495505C0 (en) 2024-09-11
US11920182B2 (en) 2024-03-05
EP2971098A1 (en) 2016-01-20
BR112015022141A2 (pt) 2017-08-29
EP3495505A1 (en) 2019-06-12
EP3495505B1 (en) 2024-09-11
US20240417774A1 (en) 2024-12-19
US11104934B2 (en) 2021-08-31
CA2903488A1 (en) 2014-09-25
US20210371900A1 (en) 2021-12-02
JP2016515216A (ja) 2016-05-26
EP2971098B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
EA201591286A1 (ru) Количественная оценка эффективности кэп матричной рнк
EA201591283A1 (ru) Количественная оценка эффективности кэп матричной рнк
EA201492101A1 (ru) Антитела против fcrn
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
HK1217971A1 (zh) 用於核酸分析的方法、組合物和試劑盒
PH12015502039A1 (en) Anti-lag-3 binding proteins
EA201400709A1 (ru) Молекула биспецифического антитела
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
BR112014001026A2 (pt) codificação de matriz de amostra de baixo atrasdo
IN2015DN00143A (ru)
IN2015DN00636A (ru)
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1222180A1 (zh) 用於生物樣品中的具有提高的性能的 測定
CL2015000752A1 (es) Nuevos ligandos de rig-i y metodos para producirlos
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
PH12016500753B1 (en) Antibodies specific to fcrn
PT3084432T (pt) Quantificação de glucocorticoides em escamas de peixe, espinhas, raios de barbatana ou otólitos como biomarcadores para stresse crónico
MX2017011198A (es) Biomarcadores para preeclampsia.
GB2495884A (en) A method of increasing the effect of an activated-potentiated form of an antibody
MX368486B (es) Plantas cucurbitaceas androceas, metodos de obtencion y usos de dichas plantas cucurbitaceas.
BR112013032223A2 (pt) molécula de ácido nucleico isolada, e, composição
BR112017022635A2 (pt) anticorpo de igf-1r e seu uso para diagnóstico de câncer